Ethical challenges raised by osteoporosis-related clinical trials
Abstract
Osteoporosis has a significant economy, society, and health burden. The recent advancement of available therapies caused ethical questions regarding the use of placebo-controlled studies in osteoporosis. Some specialists believe it is not ethically to subject the study participants to any additional risk when there is already verified effective therapy for the disease and established therapies can significantly decrease the likelihood of osteoporotic fracture. Accordingly, researchers have expressed ethical concerns over placebo-controlled trials. Here, we have briefly addressed ethical and methodological aspects regarding conducting placebo-control trials as well as potential alternatives.
Gullberg B, Johnell O, Kanis J. World-wide projections for hip fracture. Osteoporosis international. 1997; 7(5): 407-13.
Shen Y, Huang X, Wu J, Lin X, Zhou X, Zhu Z, et al. The Global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990-2019. Front Endocrinol (Lausanne). 2022; 13: 882241.
Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5(11): 898-907.
Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30(1): 3-44.
Kehoe T, Blind E, Janssen H. Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective. Br J Clin Pharmacol. 2019; 85(6): 1208-12.
Vallotton MB. Council for international organizations of medical sciences perspectives: protecting persons through international ethics guidelines. International Journal of Integrated Care. 2010;10(5).
Skierka AS, Michels KB. Ethical principles and placebo-controlled trials-interpretation and implementation of the Declaration of Helsinki's placebo paragraph in medical research. BMC Med Ethics. 2018; 19(1): 24.
Emanuel EJ, Miller FG. The ethics of placebo-controlled trials—a middle ground. Mass Medical Soc; 2001, p, 915-9.
Group ICoHEW. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. CFR & ICH Guidelines. 1997.
Miller FG, Brody H. What makes placebo-controlled trials unethical? The American Journal of Bioethics. 2002; 2(2): 3-9.
Iolascon G, Moretti A. What are the efficacy and safety of pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D? A Cochrane review summary with commentary. J Musculoskelet Neuronal Interact. 2022; 22(1): 1-4.
Howick J. Questioning the methodologic superiority of 'placebo' over 'active' controlled trials. Am J Bioeth. 2009; 9(9): 34-48.
Association WM. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20): 2191-4.
Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics. 2003; 17(2): 188-204.
Heaney RP. Evidence-based medicine and common sense: practical and ethical issues in clinical trials for osteoporosis. International Journal of Clinical Rheumatology. 2007; 2(1): 105.
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016; 316(7): 722-33.
Stein CM, Ray WA. The ethics of placebo in studies with sracture end points in osteoporosis. New England Journal of Medicine. 2010;363(14):1367-70.
Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health technology assessment (Winchester, England). 2005; 9(22): 1-160.
Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews. 2002; 23(4): 570-8.
Byun JH, Jang S, Lee S, Park S, Yoon HK, Yoon BH, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. J Bone Metab. 2017; 24(1): 37-49.
World medical association. declaration of Helsinki, ethical principles for medical research involving human subjects. 52 nd WMA general assembly, Edinburgh, Scotland. 2000.
Rosen CJ, Khosla S. Placebo-controlled trials in osteoporosis — proceeding with Caution. New England Journal of Medicine. 2010; 363(14): 1365-7.
Silverman SL, Cummings SR, Watts NB, for the consensus panel of the ASBMR I, NOF. recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American society for bone and mineral research (ASBMR), the International society for clinical densitometry (ISCD), and the national osteoporosis foundation (NOF). Journal of Bone and Mineral Research. 2008; 23(1): 159-65.
Brody BA, Dickey N, Ellenberg SS, Heaney RP, Levine RJ, O'brien RL, et al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? Journal of Bone and Mineral Research. 2003; 18(6): 1105-9.
Tanne JH. FDA puts restrictions on an institutional review board after secret investigation. British Medical Journal Publishing Group. 2009.
Batra S, Howick J. Empirical evidence against placebo controls. J Med Ethics. 2017.
Krol FJ, Hagin M, Vieta E, Harazi R, Lotan A, Strous RD, et al. Placebo-To be or not to be? are there really alternatives to placebo-controlled trials? European Neuropsychopharmacology. 2020; 32: 1-11.
Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int. 2002; 13(1): 1-5.
| Files | ||
| Issue | Vol 16 (2023) | |
| Section | Commentary | |
| DOI | https://doi.org/10.18502/jmehm.v16i7.14302 | |
| Keywords | ||
| Osteoporosis; Placebo; Trial design; Ethics. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
